Tegal Corp (CLRX) 3.30 $CLRX
CollabRx partners with Affymetrix to develop integrated clinical cancer panels
M2 - Thu Apr 17, 7:16AM CDT
CollabRx, Inc. (NASDAQ: CLRX) and Affymetrix, Inc. (NASDAQ: AFFX) said they have announced an agreement to optimize the use of CollabRx's Genetic Variant Annotation Service in connection with Affymetrix' OncoScan FFPE Assay Kit and CytoScan Cytogenetics Suite for analysis of gene copy number variation in cancer research.
CollabRx and Affymetrix Partner To Develop Analytical Tools For Integrated Clinical Cancer Panels
PRWeb - Wed Apr 16, 8:07AM CDT
CollabRx, Inc. (NASDAQ: CLRX), a leading provider of software and IT systems that support clinical decision-making in oncology, and Affymetrix, Inc. (NASDAQ: AFFX), an industry leader in genomics analysis, today announced an agreement to optimize the use of CollabRx's Genetic Variant Annotation (GVA) Service™ in connection with Affymetrix' OncoScan™ FFPE Assay Kit and CytoScan(R) Cytogenetics Suite for analysis of gene copy number variation (CNV) in cancer research.
CollabRx Appoints Paul Billings, MD, PhD to Board of Directors
GlobeNewswire - Tue Apr 08, 8:40AM CDT
via PRWEB - CollabRx, Inc. (Nasdaq:CLRX) today announced the appointment of Paul R. Billings, MD, PhD, FACP, FACMG to its Board of Directors. Dr. Billings is a nationally recognized expert on genomic and precision medicine.
CollabRx partners with Jackson Laboratory in molecular diagnostics for cancer
M2 - Thu Apr 03, 10:27AM CDT
CollabRx, Inc. (NASDAQ: CLRX) and The Jackson Laboratory said they have announced a multi-year agreement to access CollabRx technology and content resources in support of the clinical interpretation of genetic sequencing-based tests provided by JAX.
CollabRx and The Jackson Laboratory Partner in Molecular Diagnostics for Cancer
GlobeNewswire - Wed Apr 02, 8:43AM CDT
via PRWEB - CollabRx, Inc. (NASDAQ: CLRX), a data analytics company focused on informing clinical decision-making in molecular medicine, and The Jackson Laboratory (JAX), an independent, nonprofit biomedical research institution with a staff of over 1,500 employees, today announced a multi-year agreement to access CollabRx technology and content resources in support of the clinical interpretation of genetic sequencing-based tests provided by JAX.
CollabRx: Making Sense of the Complex Cancer Market
ACCESSWIRE - Tue Apr 01, 9:02AM CDT
Cancer is one of the leading causes of death worldwide and the number of people affected by the disease is growing rapidly. In 2012, more than 14.1 million people around the world were newly diagnosed with some form of the disease. By 2035, the World Cancer Research Foundation expects these figures to increase to about 24 million new cases. These dynamics have attracted record numbers of researchers developing new therapeutics, diagnostics, and other tools designed to better treat patients.
Taglich Brothers Initiates Coverage on CollabRx Inc. (NASDAQ:CLRX) with Speculative Buy Recommendation - Video Research Alert on InvestmentPitch.com
Thomson Reuters ONE - Wed Mar 19, 10:09AM CDT
Vancouver, BC, March 19, 2014 - New York based investment firm Taglich Brothers has initiated coverage on CollabRx Inc. (NASDAQ:CLRX). Analyst Juan Noble gives the company a speculative buy rating, and a 12 month price target of $10.00, a premium of 188% to the $3.47 price on February 25th, the day the report was issued.
CollabRx Appoints Clifford Baron as Chief Operating Officer
GlobeNewswire - Wed Mar 05, 8:01AM CST
CollabRx, Inc. (Nasdaq:CLRX) today announced the appointment of Clifford Baron, PhD as Vice President and Chief Operating Officer. Mr. Baron's most recent position was with Accelrys, Inc. a $160M+ global software provider serving pharmaceutical, biotechnology, chemical, and materials corporations.
Taglich Brothers Initiates Coverage on CollabRx, Inc.
Marketwire - Mon Mar 03, 9:01AM CST
Taglich Brothers, Inc. announces it initiated coverage of CollabRx, Inc.
10-Q: COLLABRX, INC.
Edgar Online - Thu Feb 13, 1:06PM CST
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations - (Amounts in thousands)
CollabRx Reports Third Quarter Fiscal Year 2014 Financial Results
GlobeNewswire - Tue Feb 11, 3:01PM CST
CollabRx, Inc. (the "Company"
(Nasdaq:CLRX) today announced financial results for the third quarter of fiscal year 2014, which ended December 31, 2013.
CollabRx, Inc. Schedules Third Quarter Fiscal Year 2014 Financial Conference Call and Business Update
GlobeNewswire - Fri Jan 31, 8:01AM CST
CollabRx, Inc. (Nasdaq:CLRX), a data analytics company focused on genomics, today announced that it will hold an investor conference call on February 11, 2014 to discuss the Company's financial results for the third quarter of fiscal 2014 and to provide an update about the business in the current fiscal year.
CollabRx and CellNetix Partner to Advance Molecular Testing in Oncology
M2 - Tue Jan 28, 9:37AM CST
CollabRx, Inc. (NASDAQ: CLRX) and CellNetix Pathology & Laboratories, LLC, have announced a multi-year agreement to access CollabRx technology and content resources in support of the clinical interpretation of genetic sequencing-based tests provided by CellNetix.
CollabRx to Present at the Sixth Annual Personalized Medicine World Conference
GlobeNewswire - Tue Jan 21, 8:01AM CST
CollabRx, Inc. (Nasdaq:CLRX), a data analytics company focused on informing clinical decision making in molecular medicine, announces that Gavin J. Gordon, MBA, PhD, Vice President of Business Development & Strategic Alliances, will present in Track 2 (Big Data: Storage and Management) at the Personalized Medicine World Conference (PMWC) at 2 PM (PST) on January 28, 2014. The PMWC will be held January 26-28 at the Computer History Museum, 1401 N. Shoreline Blvd, Mountain View, California. The PMWC will include presentations and panel discussions from over 100 industry leaders from around the world.
CollabRx Launches New Web App for Cynvenio's ClearID Breast Cancer Patients
GlobeNewswire - Wed Jan 15, 8:01AM CST
CollabRx, Inc. (Nasdaq:CLRX), a leading data analytics company, today announced that its newest Therapy Finder for breast cancer patients will be made available in connection with the Cynvenio ClearID(TM) Breast Cancer genomic blood test. This announcement extends the scope of a previously disclosed multi-year agreement which announced the pairing of the CollabRx Genetic Variant Annotation (GVA) Service(TM) with tumor mutation profiling from whole blood provided by Cynvenio.
Cynvenio and CollabRx Announce Partnership for Cancer Molecular Diagnostics
PRWeb - Wed Dec 11, 8:23AM CST
Cynvenio, a cancer diagnostics company focused on transforming cancer treatment and management through the genomic analysis of tumor cells in blood, today announced a multi-year agreement with CollabRx, Inc., a data analytics company focused on informing clinical decision making in molecular medicine, to offer clinical actionable reports built from CollabRx data and information services with Cynvenio genomic tests.
CollabRx partners with Affymetrix to develop integrated clinical cancer panels
M2 - Thu Apr 17, 7:16AM CDT
CollabRx, Inc. (NASDAQ: CLRX) and Affymetrix, Inc. (NASDAQ: AFFX) said they have announced an agreement to optimize the use of CollabRx's Genetic Variant Annotation Service in connection with Affymetrix' OncoScan FFPE Assay Kit and CytoScan Cytogenetics Suite for analysis of gene copy number variation in cancer research.
CollabRx and Affymetrix Partner To Develop Analytical Tools For Integrated Clinical Cancer Panels
PRWeb - Wed Apr 16, 8:07AM CDT
CollabRx, Inc. (NASDAQ: CLRX), a leading provider of software and IT systems that support clinical decision-making in oncology, and Affymetrix, Inc. (NASDAQ: AFFX), an industry leader in genomics analysis, today announced an agreement to optimize the use of CollabRx's Genetic Variant Annotation (GVA) Service™ in connection with Affymetrix' OncoScan™ FFPE Assay Kit and CytoScan(R) Cytogenetics Suite for analysis of gene copy number variation (CNV) in cancer research.
CollabRx Appoints Paul Billings, MD, PhD to Board of Directors
GlobeNewswire - Tue Apr 08, 8:40AM CDT
via PRWEB - CollabRx, Inc. (Nasdaq:CLRX) today announced the appointment of Paul R. Billings, MD, PhD, FACP, FACMG to its Board of Directors. Dr. Billings is a nationally recognized expert on genomic and precision medicine.
CollabRx partners with Jackson Laboratory in molecular diagnostics for cancer
M2 - Thu Apr 03, 10:27AM CDT
CollabRx, Inc. (NASDAQ: CLRX) and The Jackson Laboratory said they have announced a multi-year agreement to access CollabRx technology and content resources in support of the clinical interpretation of genetic sequencing-based tests provided by JAX.
CollabRx and The Jackson Laboratory Partner in Molecular Diagnostics for Cancer
GlobeNewswire - Wed Apr 02, 8:43AM CDT
via PRWEB - CollabRx, Inc. (NASDAQ: CLRX), a data analytics company focused on informing clinical decision-making in molecular medicine, and The Jackson Laboratory (JAX), an independent, nonprofit biomedical research institution with a staff of over 1,500 employees, today announced a multi-year agreement to access CollabRx technology and content resources in support of the clinical interpretation of genetic sequencing-based tests provided by JAX.
CollabRx: Making Sense of the Complex Cancer Market
ACCESSWIRE - Tue Apr 01, 9:02AM CDT
Cancer is one of the leading causes of death worldwide and the number of people affected by the disease is growing rapidly. In 2012, more than 14.1 million people around the world were newly diagnosed with some form of the disease. By 2035, the World Cancer Research Foundation expects these figures to increase to about 24 million new cases. These dynamics have attracted record numbers of researchers developing new therapeutics, diagnostics, and other tools designed to better treat patients.
Taglich Brothers Initiates Coverage on CollabRx Inc. (NASDAQ:CLRX) with Speculative Buy Recommendation - Video Research Alert on InvestmentPitch.com
Thomson Reuters ONE - Wed Mar 19, 10:09AM CDT
Vancouver, BC, March 19, 2014 - New York based investment firm Taglich Brothers has initiated coverage on CollabRx Inc. (NASDAQ:CLRX). Analyst Juan Noble gives the company a speculative buy rating, and a 12 month price target of $10.00, a premium of 188% to the $3.47 price on February 25th, the day the report was issued.
CollabRx Appoints Clifford Baron as Chief Operating Officer
GlobeNewswire - Wed Mar 05, 8:01AM CST
CollabRx, Inc. (Nasdaq:CLRX) today announced the appointment of Clifford Baron, PhD as Vice President and Chief Operating Officer. Mr. Baron's most recent position was with Accelrys, Inc. a $160M+ global software provider serving pharmaceutical, biotechnology, chemical, and materials corporations.
Taglich Brothers Initiates Coverage on CollabRx, Inc.
Marketwire - Mon Mar 03, 9:01AM CST
Taglich Brothers, Inc. announces it initiated coverage of CollabRx, Inc.
10-Q: COLLABRX, INC.
Edgar Online - Thu Feb 13, 1:06PM CST
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations - (Amounts in thousands)
CollabRx Reports Third Quarter Fiscal Year 2014 Financial Results
GlobeNewswire - Tue Feb 11, 3:01PM CST
CollabRx, Inc. (the "Company"
(Nasdaq:CLRX) today announced financial results for the third quarter of fiscal year 2014, which ended December 31, 2013. CollabRx, Inc. Schedules Third Quarter Fiscal Year 2014 Financial Conference Call and Business Update
GlobeNewswire - Fri Jan 31, 8:01AM CST
CollabRx, Inc. (Nasdaq:CLRX), a data analytics company focused on genomics, today announced that it will hold an investor conference call on February 11, 2014 to discuss the Company's financial results for the third quarter of fiscal 2014 and to provide an update about the business in the current fiscal year.
CollabRx and CellNetix Partner to Advance Molecular Testing in Oncology
M2 - Tue Jan 28, 9:37AM CST
CollabRx, Inc. (NASDAQ: CLRX) and CellNetix Pathology & Laboratories, LLC, have announced a multi-year agreement to access CollabRx technology and content resources in support of the clinical interpretation of genetic sequencing-based tests provided by CellNetix.
CollabRx to Present at the Sixth Annual Personalized Medicine World Conference
GlobeNewswire - Tue Jan 21, 8:01AM CST
CollabRx, Inc. (Nasdaq:CLRX), a data analytics company focused on informing clinical decision making in molecular medicine, announces that Gavin J. Gordon, MBA, PhD, Vice President of Business Development & Strategic Alliances, will present in Track 2 (Big Data: Storage and Management) at the Personalized Medicine World Conference (PMWC) at 2 PM (PST) on January 28, 2014. The PMWC will be held January 26-28 at the Computer History Museum, 1401 N. Shoreline Blvd, Mountain View, California. The PMWC will include presentations and panel discussions from over 100 industry leaders from around the world.
CollabRx Launches New Web App for Cynvenio's ClearID Breast Cancer Patients
GlobeNewswire - Wed Jan 15, 8:01AM CST
CollabRx, Inc. (Nasdaq:CLRX), a leading data analytics company, today announced that its newest Therapy Finder for breast cancer patients will be made available in connection with the Cynvenio ClearID(TM) Breast Cancer genomic blood test. This announcement extends the scope of a previously disclosed multi-year agreement which announced the pairing of the CollabRx Genetic Variant Annotation (GVA) Service(TM) with tumor mutation profiling from whole blood provided by Cynvenio.
Cynvenio and CollabRx Announce Partnership for Cancer Molecular Diagnostics
PRWeb - Wed Dec 11, 8:23AM CST
Cynvenio, a cancer diagnostics company focused on transforming cancer treatment and management through the genomic analysis of tumor cells in blood, today announced a multi-year agreement with CollabRx, Inc., a data analytics company focused on informing clinical decision making in molecular medicine, to offer clinical actionable reports built from CollabRx data and information services with Cynvenio genomic tests.
